CSTL Key Statistics, Chart & Performance
The current stock price of CSTL is 39.95 USD. In the past month the price increased by 65.01%. In the past year, price increased by 31.94%.
CSTL Latest News, Press Relases and Analysis
CSTL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.73 | 102.01B | ||
| CI | THE CIGNA GROUP | 9.76 | 74.07B | ||
| LH | LABCORP HOLDINGS INC | 16.99 | 22.28B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 118.13 | 21.73B | ||
| DGX | QUEST DIAGNOSTICS INC | 19.38 | 21.04B | ||
| GH | GUARDANT HEALTH INC | N/A | 13.97B | ||
| HIMS | HIMS & HERS HEALTH INC | 73.63 | 9.05B | ||
| DVA | DAVITA INC | 12.97 | 8.45B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 35.45 | 6.52B | ||
| RDNT | RADNET INC | 217.87 | 6.39B | ||
| CHE | CHEMED CORP | 19.96 | 6.22B | ||
| OPCH | OPTION CARE HEALTH INC | 20.87 | 4.94B |
Related stock screener links
About CSTL
Company Profile
Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The company is headquartered in Friendswood, Texas and currently employs 761 full-time employees. The company went IPO on 2019-07-25. The firm offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. The company also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). The company also focused on chronic acid reflux related diseases, including esophageal cancer.
Company Info
CASTLE BIOSCIENCES INC
505 S Friendswood Drive, Suite 401
Friendswood TEXAS 77546 US
CEO: Derek J. Maetzold
Employees: 761
Phone: 18667889007
CASTLE BIOSCIENCES INC / CSTL FAQ
What does CSTL do?
Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The company is headquartered in Friendswood, Texas and currently employs 761 full-time employees. The company went IPO on 2019-07-25. The firm offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. The company also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). The company also focused on chronic acid reflux related diseases, including esophageal cancer.
What is the current price of CSTL stock?
The current stock price of CSTL is 39.95 USD. The price increased by 0.03% in the last trading session.
What is the dividend status of CASTLE BIOSCIENCES INC?
CSTL does not pay a dividend.
How is the ChartMill rating for CASTLE BIOSCIENCES INC?
CSTL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the Price/Earnings (PE) ratio of CASTLE BIOSCIENCES INC (CSTL)?
The PE ratio for CASTLE BIOSCIENCES INC (CSTL) is 153.65. This is based on the reported non-GAAP earnings per share of 0.26 and the current share price of 39.95 USD.
What is the market capitalization of CSTL stock?
CASTLE BIOSCIENCES INC (CSTL) has a market capitalization of 1.17B USD. This makes CSTL a Small Cap stock.
What is the ownership structure of CASTLE BIOSCIENCES INC (CSTL)?
You can find the ownership structure of CASTLE BIOSCIENCES INC (CSTL) on the Ownership tab.
CSTL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to CSTL. When comparing the yearly performance of all stocks, CSTL is one of the better performing stocks in the market, outperforming 93.22% of all stocks.
CSTL Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to CSTL. No worries on liquidiy or solvency for CSTL as it has an excellent financial health rating, but there are worries on the profitability.
CSTL Financial Highlights
Over the last trailing twelve months CSTL reported a non-GAAP Earnings per Share(EPS) of 0.26. The EPS increased by 30% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.17% | ||
| ROE | -2.62% | ||
| Debt/Equity | 0.02 |
CSTL Forecast & Estimates
14 analysts have analysed CSTL and the average price target is 37.99 USD. This implies a price decrease of -4.89% is expected in the next year compared to the current price of 39.95.
For the next year, analysts expect an EPS growth of -393.05% and a revenue growth -3.02% for CSTL